Matches in SemOpenAlex for { <https://semopenalex.org/work/W4361947940> ?p ?o ?g. }
Showing items 1 to 88 of
88
with 100 items per page.
- W4361947940 abstract "<div>Abstract<p><b>Purpose:</b> The purpose of this study was to evaluate safety, pharmacokinetics, pharmacodynamics, and preliminary antitumor efficacy of ARGX-110, a glyco-engineered monoclonal antibody, targeting CD70, in patients with CD70 expressing advanced malignancies.</p><p><b>Experimental Design:</b> Dose escalation with a sequential 3+3 design was performed in five steps at the 0.1, 1, 2, 5, and 10 mg/kg dose levels (<i>N</i> = 26). ARGX-110 was administered intravenously every 3 weeks until progression or intolerable toxicity. Dose-limiting toxicity was evaluated in the 21 days following the first ARGX-110 administration (Cycle 1). Samples for pharmacokinetics and pharmacodynamics were collected.</p><p><b>Results:</b> Dose-limiting toxicity was not observed and the maximum tolerated dose was not reached. ARGX-110 was generally well tolerated, with no dose-related increase in treatment-emergent adverse events (TEAE). The most common TEAE were fatigue and drug related infusion-related reactions (IRR). Of the 20 SAEs reported, five events, all IRRs, were considered related to ARGX-110. ARGX-110 demonstrates dose proportionality over the dose range 1 to 10 mg/kg, but not at 0.1 mg/kg and a terminal half-life of 10 to 13 days. The best overall response was stable disease (14/26) in all 26 evaluable patients with various malignancies and the mean duration of treatment was 15 weeks. No dose–response related antitumor activity was observed, but biomarker readouts provided signs of biological activity, particularly in patients with hematologic malignancies.</p><p><b>Conclusions:</b> This dose-escalation phase I trial provides evidence of good tolerability of ARGX-110, pharmacokinetics, and preliminary antitumor activity at all dose levels in generally heavily pretreated patients with advanced CD70-positive malignancies. <i>Clin Cancer Res; 23(21); 6411–20. ©2017 AACR</i>.</p></div>" @default.
- W4361947940 created "2023-04-05" @default.
- W4361947940 creator A5010064853 @default.
- W4361947940 creator A5011625621 @default.
- W4361947940 creator A5015773919 @default.
- W4361947940 creator A5019216062 @default.
- W4361947940 creator A5021624793 @default.
- W4361947940 creator A5021807846 @default.
- W4361947940 creator A5024390084 @default.
- W4361947940 creator A5024463400 @default.
- W4361947940 creator A5032462496 @default.
- W4361947940 creator A5043348199 @default.
- W4361947940 creator A5053031492 @default.
- W4361947940 creator A5054416214 @default.
- W4361947940 creator A5062770314 @default.
- W4361947940 creator A5073344530 @default.
- W4361947940 creator A5074506844 @default.
- W4361947940 creator A5078388793 @default.
- W4361947940 creator A5081212841 @default.
- W4361947940 creator A5082291642 @default.
- W4361947940 creator A5086777523 @default.
- W4361947940 creator A5091335864 @default.
- W4361947940 date "2023-03-31" @default.
- W4361947940 modified "2023-10-14" @default.
- W4361947940 title "Data from Phase I Dose-Escalation Study of the Anti-CD70 Antibody ARGX-110 in Advanced Malignancies" @default.
- W4361947940 doi "https://doi.org/10.1158/1078-0432.c.6527006" @default.
- W4361947940 hasPublicationYear "2023" @default.
- W4361947940 type Work @default.
- W4361947940 citedByCount "0" @default.
- W4361947940 crossrefType "posted-content" @default.
- W4361947940 hasAuthorship W4361947940A5010064853 @default.
- W4361947940 hasAuthorship W4361947940A5011625621 @default.
- W4361947940 hasAuthorship W4361947940A5015773919 @default.
- W4361947940 hasAuthorship W4361947940A5019216062 @default.
- W4361947940 hasAuthorship W4361947940A5021624793 @default.
- W4361947940 hasAuthorship W4361947940A5021807846 @default.
- W4361947940 hasAuthorship W4361947940A5024390084 @default.
- W4361947940 hasAuthorship W4361947940A5024463400 @default.
- W4361947940 hasAuthorship W4361947940A5032462496 @default.
- W4361947940 hasAuthorship W4361947940A5043348199 @default.
- W4361947940 hasAuthorship W4361947940A5053031492 @default.
- W4361947940 hasAuthorship W4361947940A5054416214 @default.
- W4361947940 hasAuthorship W4361947940A5062770314 @default.
- W4361947940 hasAuthorship W4361947940A5073344530 @default.
- W4361947940 hasAuthorship W4361947940A5074506844 @default.
- W4361947940 hasAuthorship W4361947940A5078388793 @default.
- W4361947940 hasAuthorship W4361947940A5081212841 @default.
- W4361947940 hasAuthorship W4361947940A5082291642 @default.
- W4361947940 hasAuthorship W4361947940A5086777523 @default.
- W4361947940 hasAuthorship W4361947940A5091335864 @default.
- W4361947940 hasConcept C111113717 @default.
- W4361947940 hasConcept C112705442 @default.
- W4361947940 hasConcept C126322002 @default.
- W4361947940 hasConcept C127413603 @default.
- W4361947940 hasConcept C188198153 @default.
- W4361947940 hasConcept C197934379 @default.
- W4361947940 hasConcept C2777334693 @default.
- W4361947940 hasConcept C29730261 @default.
- W4361947940 hasConcept C71924100 @default.
- W4361947940 hasConcept C78519656 @default.
- W4361947940 hasConcept C98274493 @default.
- W4361947940 hasConceptScore W4361947940C111113717 @default.
- W4361947940 hasConceptScore W4361947940C112705442 @default.
- W4361947940 hasConceptScore W4361947940C126322002 @default.
- W4361947940 hasConceptScore W4361947940C127413603 @default.
- W4361947940 hasConceptScore W4361947940C188198153 @default.
- W4361947940 hasConceptScore W4361947940C197934379 @default.
- W4361947940 hasConceptScore W4361947940C2777334693 @default.
- W4361947940 hasConceptScore W4361947940C29730261 @default.
- W4361947940 hasConceptScore W4361947940C71924100 @default.
- W4361947940 hasConceptScore W4361947940C78519656 @default.
- W4361947940 hasConceptScore W4361947940C98274493 @default.
- W4361947940 hasLocation W43619479401 @default.
- W4361947940 hasOpenAccess W4361947940 @default.
- W4361947940 hasPrimaryLocation W43619479401 @default.
- W4361947940 hasRelatedWork W1758514097 @default.
- W4361947940 hasRelatedWork W1997101420 @default.
- W4361947940 hasRelatedWork W2002058825 @default.
- W4361947940 hasRelatedWork W2010116591 @default.
- W4361947940 hasRelatedWork W2065816581 @default.
- W4361947940 hasRelatedWork W2074629895 @default.
- W4361947940 hasRelatedWork W2090099591 @default.
- W4361947940 hasRelatedWork W2227061539 @default.
- W4361947940 hasRelatedWork W2594910449 @default.
- W4361947940 hasRelatedWork W2992709639 @default.
- W4361947940 isParatext "false" @default.
- W4361947940 isRetracted "false" @default.
- W4361947940 workType "article" @default.